vs
Side-by-side financial comparison of MATERION Corp (MTRN) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $549.8M, roughly 1.1× MATERION Corp). Royalty Pharma plc runs the higher net margin — 34.4% vs 3.5%, a 30.9% gap on every dollar of revenue. On growth, MATERION Corp posted the faster year-over-year revenue change (30.8% vs 4.8%). Over the past eight quarters, MATERION Corp's revenue compounded faster (13.6% CAGR vs 4.6%).
Materion Corp. is a multinational company specializing in high-performance advanced materials. Among its products are advanced beryllium metals, thin film deposition materials, high-performance alloys and composites, specialty engineered beryllium, engineered metals, technical ceramics, tantalum, niobium, other precious and non-precious metals, inorganic chemicals, and specialty coatings.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
MTRN vs RPRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $549.8M | $622.0M |
| Net Profit | $19.4M | $214.2M |
| Gross Margin | 14.9% | — |
| Operating Margin | 5.1% | 62.4% |
| Net Margin | 3.5% | 34.4% |
| Revenue YoY | 30.8% | 4.8% |
| Net Profit YoY | 9.5% | 2.9% |
| EPS (diluted) | — | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $549.8M | — | ||
| Q4 25 | $489.8M | $622.0M | ||
| Q3 25 | $444.8M | $609.3M | ||
| Q2 25 | $431.7M | $578.7M | ||
| Q1 25 | $420.3M | $568.2M | ||
| Q4 24 | $436.9M | $593.6M | ||
| Q3 24 | $436.7M | $564.7M | ||
| Q2 24 | $425.9M | $537.3M |
| Q1 26 | $19.4M | — | ||
| Q4 25 | $6.6M | $214.2M | ||
| Q3 25 | $25.4M | $288.2M | ||
| Q2 25 | $25.1M | $30.2M | ||
| Q1 25 | $17.7M | $238.3M | ||
| Q4 24 | $-48.9M | $208.2M | ||
| Q3 24 | $22.3M | $544.0M | ||
| Q2 24 | $19.0M | $102.0M |
| Q1 26 | 14.9% | — | ||
| Q4 25 | 13.0% | — | ||
| Q3 25 | 19.4% | — | ||
| Q2 25 | 19.1% | — | ||
| Q1 25 | 18.1% | — | ||
| Q4 24 | 21.3% | — | ||
| Q3 24 | 18.5% | — | ||
| Q2 24 | 19.0% | — |
| Q1 26 | 5.1% | — | ||
| Q4 25 | 2.2% | 62.4% | ||
| Q3 25 | 7.9% | 70.1% | ||
| Q2 25 | 8.5% | 36.3% | ||
| Q1 25 | 6.5% | 94.0% | ||
| Q4 24 | -8.8% | 60.9% | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 7.5% | 50.2% |
| Q1 26 | 3.5% | — | ||
| Q4 25 | 1.3% | 34.4% | ||
| Q3 25 | 5.7% | 47.3% | ||
| Q2 25 | 5.8% | 5.2% | ||
| Q1 25 | 4.2% | 41.9% | ||
| Q4 24 | -11.2% | 35.1% | ||
| Q3 24 | 5.1% | 96.3% | ||
| Q2 24 | 4.5% | 19.0% |
| Q1 26 | — | — | ||
| Q4 25 | $0.30 | $0.49 | ||
| Q3 25 | $1.22 | $0.67 | ||
| Q2 25 | $1.21 | $0.07 | ||
| Q1 25 | $0.85 | $0.55 | ||
| Q4 24 | $-2.34 | $0.46 | ||
| Q3 24 | $1.07 | $1.21 | ||
| Q2 24 | $0.91 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.2M | $618.7M |
| Total DebtLower is stronger | $489.9M | $9.0B |
| Stockholders' EquityBook value | $957.0M | $9.7B |
| Total Assets | $1.9B | $19.6B |
| Debt / EquityLower = less leverage | 0.51× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $16.2M | — | ||
| Q4 25 | $13.7M | $618.7M | ||
| Q3 25 | $16.4M | $938.9M | ||
| Q2 25 | $12.6M | $631.9M | ||
| Q1 25 | $15.6M | $1.1B | ||
| Q4 24 | $16.7M | $929.0M | ||
| Q3 24 | $17.9M | $950.1M | ||
| Q2 24 | $17.1M | $1.8B |
| Q1 26 | $489.9M | — | ||
| Q4 25 | $460.6M | $9.0B | ||
| Q3 25 | $458.9M | $8.9B | ||
| Q2 25 | $427.6M | $8.0B | ||
| Q1 25 | $453.0M | $7.6B | ||
| Q4 24 | $443.9M | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B |
| Q1 26 | $957.0M | — | ||
| Q4 25 | $943.3M | $9.7B | ||
| Q3 25 | $934.6M | $9.6B | ||
| Q2 25 | $910.6M | $9.5B | ||
| Q1 25 | $887.9M | $9.8B | ||
| Q4 24 | $868.9M | $10.3B | ||
| Q3 24 | $931.9M | $10.3B | ||
| Q2 24 | $907.1M | $9.8B |
| Q1 26 | $1.9B | — | ||
| Q4 25 | $1.8B | $19.6B | ||
| Q3 25 | $1.8B | $19.3B | ||
| Q2 25 | $1.7B | $18.3B | ||
| Q1 25 | $1.8B | $17.6B | ||
| Q4 24 | $1.7B | $18.2B | ||
| Q3 24 | $1.9B | $18.0B | ||
| Q2 24 | $1.8B | $17.7B |
| Q1 26 | 0.51× | — | ||
| Q4 25 | 0.49× | 0.92× | ||
| Q3 25 | 0.49× | 0.93× | ||
| Q2 25 | 0.47× | 0.84× | ||
| Q1 25 | 0.51× | 0.78× | ||
| Q4 24 | 0.51× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $827.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $19.5M | $827.1M | ||
| Q3 25 | $18.3M | $702.6M | ||
| Q2 25 | $49.9M | $364.0M | ||
| Q1 25 | $15.5M | $596.1M | ||
| Q4 24 | $76.3M | $742.5M | ||
| Q3 24 | $5.1M | $703.6M | ||
| Q2 24 | $20.3M | $658.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $3.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-24.3M | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -5.6% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 6.7% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.97× | 3.86× | ||
| Q3 25 | 0.72× | 2.44× | ||
| Q2 25 | 1.99× | 12.06× | ||
| Q1 25 | 0.88× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 0.23× | 1.29× | ||
| Q2 24 | 1.07× | 6.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MTRN
Segment breakdown not available.
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
